Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 62.05
(0.98%)
EUR 62.05
(0.98%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 256.39 Million EUR | -28.25% |
| 2022 | 357.32 Million EUR | 36.54% |
| 2021 | 261.7 Million EUR | 30.37% |
| 2020 | 200.73 Million EUR | 6.31% |
| 2019 | 188.82 Million EUR | 63.87% |
| 2018 | 115.22 Million EUR | 8.0% |
| 2017 | 106.69 Million EUR | 2.16% |
| 2016 | 104.44 Million EUR | 5.43% |
| 2015 | 99.06 Million EUR | -3.68% |
| 2014 | 102.85 Million EUR | 12.45% |
| 2013 | 91.45 Million EUR | -4.65% |
| 2012 | 95.91 Million EUR | -15.93% |
| 2011 | 114.08 Million EUR | 4.9% |
| 2010 | 108.75 Million EUR | 15.18% |
| 2009 | 94.41 Million EUR | 40.53% |
| 2008 | 67.19 Million EUR | 11.55% |
| 2007 | 60.23 Million EUR | 19.92% |
| 2006 | 50.22 Million EUR | -100.0% |
| 2005 | 3350.26 Billion EUR | 42431.24% |
| 2004 | 7.87 Billion EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 254.88 Million EUR | -0.59% |
| 2024 Q2 | 374.56 Million EUR | 46.96% |
| 2023 Q1 | 316.39 Million EUR | -11.45% |
| 2023 Q4 | 256.39 Million EUR | -7.13% |
| 2023 Q3 | 276.08 Million EUR | -27.35% |
| 2023 Q2 | 380.04 Million EUR | 20.12% |
| 2023 FY | 256.39 Million EUR | -28.25% |
| 2022 FY | 357.32 Million EUR | 36.54% |
| 2022 Q2 | 391.21 Million EUR | 22.58% |
| 2022 Q4 | 357.32 Million EUR | 8.55% |
| 2022 Q1 | 319.16 Million EUR | 21.96% |
| 2022 Q3 | 329.18 Million EUR | -15.86% |
| 2021 Q3 | 232.03 Million EUR | -3.47% |
| 2021 FY | 261.7 Million EUR | 30.37% |
| 2021 Q4 | 261.7 Million EUR | 12.79% |
| 2021 Q2 | 240.38 Million EUR | 23.88% |
| 2021 Q1 | 194.03 Million EUR | -3.34% |
| 2020 Q3 | 192.25 Million EUR | 0.35% |
| 2020 Q4 | 200.73 Million EUR | 4.41% |
| 2020 Q1 | 190.34 Million EUR | 0.81% |
| 2020 Q2 | 191.58 Million EUR | 0.65% |
| 2020 FY | 200.73 Million EUR | 6.31% |
| 2019 FY | 188.82 Million EUR | 63.87% |
| 2019 Q3 | 138.36 Million EUR | -7.64% |
| 2019 Q1 | 133.21 Million EUR | 15.61% |
| 2019 Q2 | 149.81 Million EUR | 12.46% |
| 2019 Q4 | 188.82 Million EUR | 36.47% |
| 2018 Q1 | 108.69 Million EUR | 1.87% |
| 2018 Q2 | 119.13 Million EUR | 9.6% |
| 2018 FY | 115.22 Million EUR | 8.0% |
| 2018 Q4 | 115.22 Million EUR | 0.15% |
| 2018 Q3 | 115.05 Million EUR | -3.42% |
| 2017 FY | 106.69 Million EUR | 2.16% |
| 2017 Q4 | 106.69 Million EUR | 8.66% |
| 2017 Q3 | 98.19 Million EUR | -13.02% |
| 2017 Q2 | 112.88 Million EUR | 0.86% |
| 2017 Q1 | 111.92 Million EUR | 7.16% |
| 2016 Q3 | 92.31 Million EUR | -10.46% |
| 2016 Q2 | 103.09 Million EUR | 12.77% |
| 2016 Q4 | 104.44 Million EUR | 13.14% |
| 2016 Q1 | 91.41 Million EUR | -7.72% |
| 2016 FY | 104.44 Million EUR | 5.43% |
| 2015 Q1 | 96.74 Million EUR | -5.94% |
| 2015 FY | 99.06 Million EUR | -3.68% |
| 2015 Q4 | 99.06 Million EUR | -0.8% |
| 2015 Q3 | 99.86 Million EUR | -5.19% |
| 2015 Q2 | 105.32 Million EUR | 8.87% |
| 2014 Q1 | 86.62 Million EUR | -5.29% |
| 2014 Q4 | 102.85 Million EUR | 13.22% |
| 2014 Q2 | 96.48 Million EUR | 11.38% |
| 2014 Q3 | 90.83 Million EUR | -5.85% |
| 2014 FY | 102.85 Million EUR | 12.45% |
| 2013 Q4 | 91.45 Million EUR | -4.6% |
| 2013 Q3 | 95.86 Million EUR | -0.12% |
| 2013 FY | 91.45 Million EUR | -4.65% |
| 2013 Q2 | 95.98 Million EUR | 3.75% |
| 2013 Q1 | 92.51 Million EUR | -3.55% |
| 2012 Q1 | 100.15 Million EUR | -12.21% |
| 2012 Q2 | 99.02 Million EUR | -1.14% |
| 2012 Q3 | 93.34 Million EUR | -5.73% |
| 2012 FY | 95.91 Million EUR | -15.93% |
| 2012 Q4 | 95.91 Million EUR | 2.75% |
| 2011 FY | 114.08 Million EUR | 4.9% |
| 2011 Q1 | 107.56 Million EUR | -1.09% |
| 2011 Q2 | 109.64 Million EUR | 1.93% |
| 2011 Q3 | 106.85 Million EUR | -2.54% |
| 2011 Q4 | 114.08 Million EUR | 6.77% |
| 2010 Q4 | 108.75 Million EUR | 0.0% |
| 2010 FY | 108.75 Million EUR | 15.18% |
| 2009 FY | 94.41 Million EUR | 40.53% |
| 2008 FY | 67.19 Million EUR | 11.55% |
| 2007 FY | 60.23 Million EUR | 19.92% |
| 2006 FY | 50.22 Million EUR | -100.0% |
| 2005 FY | 3350.26 Billion EUR | 42431.24% |
| 2004 FY | 7.87 Billion EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Atrys Health, S.A. | 332.45 Million EUR | 22.88% |
| Biotechnologies Assets SA | 10.07 Million EUR | -2444.705% |
| Pharma Mar, S.A. | 147.78 Million EUR | -73.489% |